Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Subfertility
Interventions
DRUG

Intralipid 20%

Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.

DRUG

Normal saline

Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.

All Listed Sponsors
lead

Dar El Teb Institute

OTHER

NCT02487940 - Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure | Biotech Hunter | Biotech Hunter